ARTÍCULO ORIGINAL

LONG TERM EFFECT OF THIAZIDES ON BONE MASS IN WOMEN WITH HYPERCALCIURIIC NEPHROLITHIASIS

EFECTO A LARGO PLAZO DE TIAZIDAS SOBRE LA MASA ÓSEA EN MUJERES CON HIPERCALCIURIA NEFROLITIASIS

Francisco R Spivacow, Armando L Negri, Elisa E del Valle
Instituto de Investigaciones Metabólicas.
Universidad del Salvador. Buenos Aires. Argentina

Nefrología, Diálisis y Trasplante 2013; 33 (4) Pag. 180 - 187

ABSTRACT
Background: Decreased bone mineral density and increased prevalence of bone fractures have been found in patients with idiopathic hypercalciuria. It is not yet clear if thiazide treatment prevent these events. Methods: We retrospectively evaluated bone mass and biochemical markers of bone turnover in response to thiazide therapy in 52 consecutive female patients with idiopathic hypercalciuria and nephrolithiasis. Patients were divided in two subgroups according to their menopausal status: 25 were pre-menopausal (Group I) and 27 were postmenopausal (Group II). Results: Osteoporosis was found in 12 patients at baseline, 9 at the lumbar spine and 6 at the femoral neck. Two were pre-menopausal and 10 were postmenopausal. Patients with osteoporosis were analyzed separately (Group III). There was a significant and persistent reduction in urinary calcium with preservation of bone mass in all the groups after a median follow-up of 51 months. Few adverse effects were found using low doses of hydrochlorothiazide / amiloride. Only in the group III we found a statistically significant an increase in BMD at the lumbar spine of 9.5% and an increase in BMD at femoral neck of 4.4% that did not reach statistical significance. Conclusions: We conclude that correction of hypercalciuria during long term treatment with low-dose hydrochlorothiazide / amiloride in women with nephrolithiasis prevents bone loss and in those with osteoporosis can lead to a significant increa

Few adverse effects were seen during treatment and no interruption of therapy was necessary.

KEYWORDS: thiazides; bone mass; hypercalciuria; nephrolithiasis

RESUMEN
Introducción: Reducción de la densidad mineral ósea y aumento de la prevalencia de fracturas óseas se han encontrado en pacientes con hipercalciuria idiopática. Aún no está claro si el tratamiento con tiazidas prevenir estos eventos. Métodos: Evaluamos retrospectivamente la masa ósea y los marcadores bioquímicos de recambio óseo en respuesta a la terapia con tiazidas en 52 pacientes femeninos consecutivos con hipercaleciuria idiopática y nefrolitiasis. Los pacientes fueron divididos en dos subgrupos de acuerdo a su estado de la menopausia: 25 fueron pre-menopáusicas (Grupo I) y 27 eran posmenopáusicas (Grupo II). Resultados: La osteoporosis se encontró en 12 pacientes al inicio del estudio, 9 en la columna lumbar y 6 en el cuello femoral. Dos eran premenopáusicas y 10 eran posmenopáusicas. Los pacientes con osteoporosis se analizaron por separado (Grupo III). Hubo una reducción significativa y persistente en el calcio urinario con la preservación de la masa ósea en todos los grupos después de una mediana de seguimiento de 51 meses. Pocos efectos adversos se encuentran utilizando dosis bajas
de hidroclorotiazida / amilorida. Sólo en el grupo III encontramos un aumento estadísticamente significativo en la DMO de la columna lumbar del 9,5% y un aumento de la densidad mineral ósea en el cuello femoral de 4,4% que no alcanzó significación estadística.

**Conclusión:** Llegamos a la conclusión de que la corrección de la hipercaleúria durante el tratamiento a largo plazo con dosis bajas de hidroclorotiazida / amilorida en mujeres con nefrolitiasis previene la pérdida ósea y en aquellos con osteoporosis puede conducir a un aumento significativo en la densidad mineral ósea en la columna lumbar. Pocos se observaron efectos adversos durante el tratamiento y no hay interrupción de la terapia era necesario.

**PALABRAS CLAVE:** Las tiazidas; masa ósea; hipercaleúria; nefrolitiasis

**INTRODUCTION**

Reduced bone mineral density (BMD) is a common finding in calcium stone forming patients (SF) principally men and in genetic hypercaleúric rats (1–7). The pathogenesis of bone mass reduction in hypercaleúria involves the interplay of many factors, some linked to the negative calcium balance produced by dietary calcium restriction recommended to patients in the past (1).

Some authors have found increased in bone resorptive activity (2). Jaeger et al (12) found a negative correlation between pyridinoline in 24 hr-urine and tibial shaft BMD. Other authors found impaired osteoblast activity without changes in the resorptive activity (10,11).

Different treatments have been used to control of hypercaleúria, irrespective of the mechanisms that causes low bone mass. Some of them include bisphosphonates (7,13), even though most consider the thiazide diuretics as the drugs of choice (14,16).

A few open-label prospective studies have suggested that thiazide diuretics may have beneficial effects on bone (15). Two randomized studies (17,19) showed modest gains in bone mass. In the same way, in a prospective randomized placebo-controlled study a small effect in preventing bone loss at the hip and spine was noted after 3 years (19).

The aim of the present study was to evaluate the long-term effects of thiazides on bone mass and bone remodeling markers when used as the only treatment in women with idiopathic hypercaleúria and nephrolithiasis.

**MATERIALS AND METHODS**

We retrospectively evaluated bone mass and biochemical markers of bone turnover in response to thiazide therapy, in 52 consecutive female patients with idiopathic hypercaleúria and nephrolithiasis. Study subjects were recruited between 2003 and 2010 among patients seen at our outpatient’s lithiasis clinic. Patients included in this report satisfied the following criteria: (a) they had idiopathic hypercaleúria (urinary calcium excretion > 220 mg/24 h or > 4 mg/Kg body weight on a normal calcium diet with normal serum calcium) b) they have passed or had a positive detection study for urinary calculi (either a plain abdominal radiograph or renal sonography); c) they had normal renal function determined by creatinine clearance (c) none had a diagnosis of primary hyperparathyroidism, intestinal fat malabsorption, distal renal tubular acidosis, systemic malignancy or liver disease (cirrhosis or hepatitis); (d) they have not been treated with calcium salts, bisphosphonates, teriparatide, SERM, strontium ranelate, fluoride, or have been on long-term glucocorticoid therapy at least one year before being included in the study.

Bone mass was assessed by Dual energy X-ray absorptiometry (DXA) using Lunar Prodigy densitometer (Lunar Corporation, General Electric, Madison, WI, USA) measured at the lumbar spine (LS) and femoral neck (FN).

Fasting morning venous blood samples were obtained before breakfast and analyzed for creatinine, calcium, phosphorus, 25 OH D, total alkaline phosphatase (ALP), bone-specific alkaline phosphatase (BAP), glucose, total cholesterol, uric acid, serum potassium and serum β crosslaps (CTX). 24-hour urine samples were obtained from each patient for determination of calcium, sodium and creatinine.

Bone densitometry was performed at baseline and during follow-up under thiazide treatment. Laboratory determinations were obtained as closely as possible to the bone mass determinations. All patients received a diuretic combination (amilorida + hydrochlorothiazide) as treatment for their hypercaleúria. Dose was adjusted according
to the reduction in urinary calcium. In addition, all patients received calcium and vitamin D in the case of deficit.

All study procedures were approved by the institutional review board of the Metabolic Research Institute (CODEI) and each study participant gave his written informed consent for the use of their clinical records for scientific purposes.

**Laboratory methods**

Serum and urine calcium, sodium and potassium were measured by ion-selective electrode (ISE) method using a Synchron CX3 automated analyzer (Beckman, Beckman Instruments inc. Brea, California. USA). Normal values for total serum calcium: 8.8-10.5 mg/dl, urinary calcium: < 220 mg/24 h, serum sodium: 136 – 145 mEq/L, serum potassium: 3.9 – 4.5 mEq/L. Creatinine (Jaffe kinetic method) and phosphate (UV) were measured using CCX Spectrum automated analyzer (Abbott Labs. USA). Normal values for serum creatinine: 0.6 – 1.1 mg/dl, Normal values for phosphate: 2.7 - 4.5 mg/dl. Uric acid was analyzed by the uricase method. Normal value: 2.5 – 5.5 mg/dl. Total alkaline phosphatase and its bone isoenzyme (Kinetic method RR: 90-280 UI/l and 20-48% respectively). Serum \( \beta \) crosslaps (CTX): electrochemiluminescence, RR: 556 ± 226 pg/ml. 25 OH D Radioinmunoanálisis, normal value: 20-40 ng/ml.

**Statistical analyses**

Changes in bone densitometry and biochemical parameters between the beginning of treatment and last follow-up were assessed by two-sided paired T-test. A \( p < 0.05 \) was considered significant.

**RESULTS**

Result are expressed in mean The whole group had a mean ± standard desviations (SD) age of 49.3 ± 12.0 years. Their weight was 59.2 ± 8.9 Kg and their BMI was 23.6 ± 2.9 Kg/height2. Patients were divided in two subgroups according to their menopausal status: 25 were pre-menopausal (mean age 39.7 ± 8.8 years, weight 58.3 ± 9.9 Kg and BMI 22.9 ± 2.9 Kg/height2) (Group I) and 27 were postmenopausal (mean age 58.1 ± 6.5 years, weight 60.0 ± 8.0 Kg and BMI 24.2 ± 2.8 Kg/height2) (Group II). Osteoporosis was found in 12 patients at baseline, 9 at the lumbar spine and 6 at the femoral neck. Two were pre-menopausal and 10 were postmenopausal. These patients were analyzed separately (Group III).

Patients were treated for median of 51 months. Urinary calcium, sodium and UCa/ KgBW index at baseline and at the end of follow up for the whole group are shown in the Table I.  

We observed a 38% decrease in urinary calcium and UCa/ KgBW index between baseline and end of follow-up, without significant changes in urinary sodium. During follow-up, urinary calcium excretion in some patients ranged from low to high values which led to increases or reductions in diuretic doses. In no case was it necessary to stop thiazide treatment because of lack of response. On the other hand, in some cases, an adjustment was made in the dietary salt, calcium and animal

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Baseline</th>
<th>End follow-up</th>
<th>% change</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>UCa mg/24 h</td>
<td>298 ± 71</td>
<td>182 ± 58</td>
<td>-38</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>UCa mg/ KgBW</td>
<td>5.0 ± 1.1</td>
<td>3.1 ± 1.1</td>
<td>-38</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>UNa mEq/24 h</td>
<td>152 ± 74</td>
<td>141 ± 55</td>
<td>-7.19</td>
<td>NS</td>
</tr>
</tbody>
</table>

Table I:

Urinary calcium, UCa/KgBW and urinary sodium at baseline and at the end of follow-up in the whole group.
protein. The average dose of hydrochlorothiazide and amiloride to achieve urinary calcium normalization was of $25.8 \pm 11.6$ and $3.75 \pm 2.5$ mg respectively. Table II, shows the changes in the three groups. We did not observe differences in the parameters measured, among the three groups of patients at the beginning and the end of follow-up. The doses of thiazide used in subgroup I was $26.5 \pm 12$ mg/d, in subgroup II the doses was $25.5 \pm 10$ mg/d, while in those with osteoporosis the doses was $28.1 \pm 14$ mg/d, without statistically significant between the three. Finally, we note that premenopausal and postmenopausal women, and those who had osteoporosis had similar values in the calciuria at baseline and also had a similar response to treatment, receiving similar doses of thiazides in all cases. Bone mass initial and final values are shown in Table III. In the total group BMD at the lumbar and femoral neck did not change significantly. Only in the group III we found an increase in BMD at the lumbar spine of $9.5\%$ that was statistically significant. Also, in the same group, we found a $4.4\%$ increase in BMD femoral neck but no reaching statistical significance, probably be-

**Table II:**
Changes in urinary calcium, UCa/KgBW and urinary sodium between baseline and end follow-up in the three groups

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Group I</th>
<th>Group II</th>
<th>Group III</th>
</tr>
</thead>
<tbody>
<tr>
<td>UCa mg/24 Hr</td>
<td>303 ± 65</td>
<td>201 ± 83*</td>
<td>293 ± 77</td>
</tr>
<tr>
<td>UCa mg/KgBW</td>
<td>5.2 ± 1.3</td>
<td>3.5 ± 1.6*</td>
<td>4.9 ± 1.0</td>
</tr>
<tr>
<td>UNa meq/24 Hr</td>
<td>159 ± 71</td>
<td>144 ± 55</td>
<td>146 ± 79</td>
</tr>
</tbody>
</table>

* <0.001 vs. baseline

**Table III:**
Changes in BMD in the three groups between baseline and the end of follow-up

<table>
<thead>
<tr>
<th>Group I</th>
<th>Group II</th>
<th>Group III</th>
</tr>
</thead>
<tbody>
<tr>
<td>LS BMD</td>
<td>1.102 ± 0.136</td>
<td>0.930 ± 0.187</td>
</tr>
<tr>
<td>FN BMD</td>
<td>0.880 ± 0.126</td>
<td>0.744 ± 0.105</td>
</tr>
</tbody>
</table>

LS BMD: Lumbar spine bone mineral density; FN BMD: Femoral neck bone mineral density

* p < 0.05 vs. baseline

because of the small number of patients. No were no changes in creatinine, calcium and serum phosphorus levels in the three subgroups analyzed. The bone remodeling parameters and 25 OH D levels are shown in Table IV. We only observed an increase of ALP in the subgroup of postmenopausal women (p < 0.05) and mainly in the group with osteoporosis in which the increase in the ALP was of $28\%$, that was statistical significance (p <0.01). The rest of mineral parameters

183
no showed significant changes. With respect to 25 OH D, the level was kept in acceptable values, during the whole follow-up, linked to the corrections of the same one with supplements. The doses of hydrochlorothiazide used in the different subgroups were 26.5 ± 12 mg (Group I), 25.5 ± 11 mg (Group II) and 28.2 ± 14 mg (Group III).

**Table IV:**
Bone remodeling markers and 25 OH D in the three groups of patients between baseline and end of follow-up

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Group I Baseline</th>
<th>End follow-up</th>
<th>Group II Baseline</th>
<th>End follow-up</th>
<th>Group III Baseline</th>
<th>End follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALP (U/L)</td>
<td>154.1 ± 73</td>
<td>175.2 ± 85</td>
<td>138.7 ± 61</td>
<td>176.9 ± 35*</td>
<td>145.8 ± 65</td>
<td>186.9 ± 51**</td>
</tr>
<tr>
<td>BAP (%)</td>
<td>31.3 ± 20.6</td>
<td>37.5 ± 5.4</td>
<td>44.3 ± 12.4</td>
<td>41.1 ± 11.2</td>
<td>42.7 ± 14.6</td>
<td>40.5 ± 10.7</td>
</tr>
<tr>
<td>CTX (pg/ml)</td>
<td>358 ± 174</td>
<td>345.8 ± 195</td>
<td>467 ± 282</td>
<td>346.7 ± 159</td>
<td>455 ± 270</td>
<td>329 ± 174</td>
</tr>
<tr>
<td>25OH D (ng/ml)</td>
<td>28.1 ± 13</td>
<td>27.9 ± 8</td>
<td>27.5 ± 13</td>
<td>31.5 ± 7</td>
<td>27.3 ± 10</td>
<td>32.1 ± 5</td>
</tr>
</tbody>
</table>

*p < 0.05 vs. baseline; **p < 0.01 vs. baseline

The serum levels of glucose, cholesterol, uric acid, sodium and potassium were analyzed in these patients as long term administration of thiazides can cause changes. Values at baseline and the end of study are shown in **Table V**.

We only found slight significant decreases in serum sodium and potassium the end of study (p < 0.01 and p < 0.05 respectively). Of all patients, mild hypokalemia (3 - 3.5 mEq/l) was observed in 5 patients (9.6%), hyperglycemia in 1 (2%), hypotension in 4 (7.7%), palpitations, cramps and headaches in 2 patients (3.8%) in each case. In no patients was it necessary to stop the medication due to adverse effects. A clear decline in kidney stones recurrence was found although it was not an aim of this study (data not shown).

**Table V:**
Changes in blood glucose, cholesterol, acid uric, sodium and potassium at baseline and end of follow-up in the whole group

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Baseline</th>
<th>End follow-up</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose mg/dl</td>
<td>88.6 ± 9.0</td>
<td>90.4 ± 19</td>
<td>NS</td>
</tr>
<tr>
<td>Cholesterol mg/dl</td>
<td>201.2 ± 29.3</td>
<td>207.5 ± 31.1</td>
<td>NS</td>
</tr>
<tr>
<td>Uric Acid mg/dl</td>
<td>4.0 ± 0.8</td>
<td>4.1 ± 0.8</td>
<td>NS</td>
</tr>
<tr>
<td>Sodium mEq/L</td>
<td>139.6 ± 5.5</td>
<td>137.1 ± 2.1</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Potassium mEq/L</td>
<td>4.6 ± 0.4</td>
<td>4.0 ± 0.3</td>
<td>&lt; 0.05</td>
</tr>
</tbody>
</table>
DISCUSSION
Our results show a significant reduction in hypercalciuria, preservation of bone mass with few adverse effects using low doses of hydrochlorothiazide/amiloride for a long period of time. The reason to use amiloride associated with a thiazide diuretic is based on the attempt to reduce the fall of the serum potassium and enhance the hypocalciuric effect. Thiazide diuretics, which inhibit sodium-chloride cotransporter (NCC) in the distal convoluted tubule, are considered as the treatment of choice for idiopathic hypercalciuria due to their hypocalciuric effect (20). The mechanism this effect and the effect of thiazides on calcium transporters in the distal convoluted tubule are still controversial. Recently Hye Ryoun et al. have suggested that TRPV5 is a critical determinant of the hypocalciuric effect of chronic HCTZ treatment (21). Amiloride is a small molecule diuretic, known to interact with the epithelial sodium channel and acid-sensing ion channel proteins, as well as sodium/hydrogen antiporters and sodium/calcium exchangers (22). With simultaneous administration of amiloride, the hypocalciuric effect of HCTZ is increased and potassium and magnesium depletion is prevented (23).

The effect of idiopathic hypercalciuria on bone has been widely evaluated in patients with calcium nephrolithiasis. Many authors have reported that the increase in urinary calcium excretion is associated with decreased bone mass and increased bone turnover in patients with kidney stones (4–6). Therefore, the reduction of the calciuria could avoid the loss of bone mass, suggested by some authors (24, 25). Using low doses of thiazides we observed a fall of 38% in urinary calcium, reaching normal ranges. Values lower than 47% were achieved after one year, by Rico et al. in 24 hypercalciuric patients (14), and as 45.9% in 14 male patients with idiopathic hypercalciuria (5 with a history of renal colic) reported by Legroux-Gerot et al. (15) with a average doses of thiazides of 44.7 ± 9.4 mg/day, for a period of 18 months, but in both cases using doses of thiazides almost twice our. The hypocalciuric effect of long term thiazide treatment (18-24 months) may have a limited action with possible return of calciuria, in some cases to levels prior to treatment, especially in the absorptive hypercalciuria (26). This seems due that the increase of calcemia that would stimulate the thyroid C cells with calcitonine production that increase the urinary excretion of calcium (27). In our patients when urinary calcium was not controlled initially, salt and animal protein was restricted and if no response was found, thiazide dose was increased.

We found no differences in urinary calcium at baseline nor in their response to thiazides when we divided patients in pre-and post-menopausal or in those with or without osteoporosis. Therefore, all had the same initial levels and the responses to thiazides were similar. In this study we found that in 52 patients with nephrolithiasis and hypercalciuria treated with thiazide/amiloride there was a small not statistically significant increase in BMD at both lumbar spine and femoral neck. Despite this, in the group III with OP (12 patients) there was a statistically significant increase in lumbar spine BMD after a median follow-up of 75.9 months; at the femoral neck BMD increased of 4.4% that was not statistically significant. Rico et al. (14) found a 5% increase in whole-body bone mass, after 1 year of treatment with thiazides. Pak et al. (28) evaluated the effects of a low calcium diet and thiazide diuretic therapy for 3 years, in 28 patients (18 men and 10 women) with absorptive hypercalciuria and found an increase of 5.7% in lumbar spine T-score, similar to the 5.4% we found at the lumbar spine but without differences in femoral neck BMD. The changes found in BMD in both lumbar spine and femoral neck in the OP group, can be explained by a closer follow-up with more stringent control in diet and thiazides doses, because these patients were not given other osteoactive medications. On the other hand the initial BMD values were lower than the other two groups, therefore giving place to greater improvements.

We found no significant changes in the different markers of mineral metabolism and bone remodeling, except for a moderate increase in ALP in both, the postmenopausal group and the group with OP. Aubin et al (29) using the cellular line of MG-63 to study the action of thiazides on osteoblasts, found that while HCTZ had no affect on cell growth and DNA synthesis but increased alkaline phosphatase activity slightly, which may reflect increased differentiation of these cells. La Croix et al. found in patients on thiazide diu-
In summary, we show that correction of hypercalciuria during long-term treatment with low-dose hydrochlorothiazide/amiloride results from hydrochlorothiazide/amiloride administration. The treatment was well tolerated during follow-up. None of the thiazide patients stopped their medication before the end of 71.3 months of the median study period. The side effect most frequent was hypokalemia, which occurred in only the 9.6% patients and required potassium supplementation in some of them. The other adverse effects were not relevant.

In summary, we show that correction of hypercalciuria during long-term treatment with low-dose hydrochlorothiazide/amiloride results in a decrease in markers for bone resorption (N-telopeptide) and bone formation (osteocalcin and BAP) but no significant changes in ionized calcium and PTH. Reductions in tartrate-resistant acid phosphatase with thiazide indicates that high rate of bone remodeling in idiopathic hypercalciuria is decreased by these drugs. The mechanism of action remains unclear but is probably due to some effects on osteoclast or 1.25OH D3. In addition, although thiazides may act directly on bone resorption, the reduction of renal calcium excretion remains the most important contributing factor to maintenance or slight improvement in bone mineral density detected in thiazide-treated subjects, and causing a sustained positive calcium balance in time as we have suggested in earlier work.

Because we did not alter the calcium intake of our patients, we suspect that the increase in bone mineral density resulted from hydrochlorothiazide/amiloride administration. Few adverse effects were seen during treatment with osteoporosis can lead to a significant increase in bone mineral density at the lumbar spine. Few adverse effects were seen during treatment and no interruption of therapy was necessary.

**REFERENCES**

18. Wasnich RD, Davis JW, HeYE, Petrovich H, Ross PD.